Juvenile spondyloarthritis+2
Not recruitingStudy of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis
Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis
- Disease:Juvenile spondyloarthritisJuvenile idiopathic arthritis+1
- Substances:AdalimumabIxekizumab
Czechia- Participants:0–17 years
- Substances:Adalimumab
- Sponsor:Eli Lilly & Co.












